Novo and Viking present new MASH data, but analysts remain confident in Madrigal’s Rezdiffranews2024-11-20T16:31:55+00:00November 20th, 2024|Endpoints News|
Updated: Sage reports Phase 2 failure in Huntington’s disease, ends drug’s developmentnews2024-11-20T12:31:28+00:00November 20th, 2024|Endpoints News|
Lilly’s oral lipid drug passes mid-stage testnews2024-11-19T15:56:21+00:00November 19th, 2024|Endpoints News|
J&J, Protagonist reveal two Phase 3 wins for oral IL-23 drug that’s expected to be a blockbusternews2024-11-19T15:54:03+00:00November 19th, 2024|Endpoints News|
#ACR24: Bristol Myers takes on autoimmune diseases with cell therapy; New data from Cabaletta and Kyvernanews2024-11-19T15:52:02+00:00November 19th, 2024|Endpoints News|
Merck finally has subcutaneous Keytruda results, and it’s going to regulatorsnews2024-11-19T12:28:39+00:00November 19th, 2024|Endpoints News|
Incyte ends enrollment in Phase 2 chronic hives trial due to preclinical safety concernsnews2024-11-19T12:18:59+00:00November 19th, 2024|Endpoints News|
Biogen, UCB detail response rates in Phase 3 lupus trial after surprising successnews2024-11-19T06:00:35+00:00November 19th, 2024|Endpoints News|
Vir, Bluejay invigorate hepatitis D space with new datanews2024-11-19T02:35:51+00:00November 19th, 2024|Endpoints News|
Rocket shares promising long-term results from rare heart disease gene therapy in small studynews2024-11-18T20:31:08+00:00November 18th, 2024|Endpoints News|
